logo
Care of patients with hepatitis C and HIV co-infection
T-cell dynamics during acute SIV infection
A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection
Detection of IgA inhibiting the interaction between gp120 and soluble CD4 receptor in serum and saliva of HIV-1-infected patients
Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level
Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era
Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection
Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy
Low mortality in HIV-infected patients starting highly active antiretroviral therapy
Maternal viral load and rate of disease progression among vertically HIV-1-infected children
Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program
HIV-1 superinfections
Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV–hepatitis C virus co-infection
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients
Are untimed antiretroviral drug levels useful predictors of adherence behavior?
Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
Can HIV-1 superinfection compromise antiretroviral therapy?
Update on chronic hepatitis C in HIV/HCV-coinfected patients